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RESUME: 
La cicatrisation cutanée requiert de nombreux mécanismes et un nombre 
toujours croissant de molécules participant à ces réactions sont identifiées. La 
compréhension de cette cinétique et des différents facteurs impliqués dans ce 
processus permet d'accélérer la guérison des plaies. Certains facteurs de 
croissance (PDGF, FGF, EGF) ont déjà été utilisés localement sur des plaies 
mais leurs effets relatés sont inconsistants et contradictoires, probablement en 
raison de l'absence de cinétique ou de concentration physiologique. Les 
plaquettes jouent un rôle fondamental dans la cicatrisation cutanée, 
principalement par la formation du clou plaquettaire et le relargage de divers 
facteurs de croissance et de cytokines. De même, les kératinocytes ont un rôle 
similaire dans l'épithélialisation des plaies. Ainsi, l'apport de plaquettes et de 
kératinocytes sur une plaie pourrait accélérer sa cicatrisation. 
L'étude rapportée ici tente de vérifier si une solution de kératinocytes autologues 
en suspension dans un concentré plaquettaire ou un concentré plaquettaire seul 
pourrait stimuler la cicatrisation cutanée. Pour ce faire, nous avons comparé trois 
groupes de 15 patients bénéficiant, sur une prise de greffe de profondeur 
similaire, d'un traitement standard fait de pansement simple, d'un concentré 
plaquettaire seul ou de kératinocytes autologues suspendus dans un concentré 
plaquettaire. Sur ces plaies, la durée de cicatrisation ainsi que la douleur au 
cours de la guérison ont été étudiés. 
Nos résultats montrent une réduction significative de la durée de cicatrisation 
dans le groupe traité avec un concentré plaquettaire, passant de 13.9 +/- 0.5 à 
7.2 +/- 0.2 jours. Cet effet est encore plus marqué dans le groupe traité avec des 
kératinocytes en suspension dans un concentré plaquettaire passant de 13.9 +/-
0.5 à 5.7 +/- 0.2 jours. De même, la douleur évaluée au cinquième jour montre 
une nette diminution dans les deux groupes traités avec des cellules. 
En conclusion, notre travail montre que l'application de plaquettes autologues ou 
de kératinocytes en suspension dans un concentré plaquettaire permet 
d'accélérer la cicatrisation cutanée et de diminuer les douleurs, sans aucun effet 
indésirable constaté. Notre étude montre également qu'un concentré plaquettaire 
peut être utilisé comme vecteur pour une suspension de kératinocytes. 
L'identification de la cinétique d'apparition et de la concentration de chacun des 
facteurs de croissance lors de la cicatrisation cutanée permettrait dans le futur 
d'analyser plus finement et de traiter physiologiquement des plaies chroniques. 
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Autologous keratinocyte suspension in platelet 
concentrate accelerates and enhances wound 
healing - a prospective randomized clinical trial 
on skin graft donor sites: platelet concentrate and 
keratinocytes on donor sites 
Sarnia Guerid 1, Salim E Darwiche 1, Mette M Berger2, Lee Ann Applegate3, Messod Benathan1 and Wassim Raffou1 1* 
Abstract 
Background: Wound healing involves complex mechanisms, which, if properly chaperoned, can enhance patient 
recovery. The abilities of platelets and keratinocytes may be harnessed in order to stimulate wound healing through 
the formation of platelet clots, the release of several growth factors and cytokines, and cell proliferation. The aim of 
the study was to test whéther autologous keratinocyte suspensions in platelet concentrate would improve wound 
healing. The study was conducted at the Lausanne University Hospital, Switzerland in 45 patients, randomized to 
three different topical treatment groups: standard treatment serving as control, autologous platelet concentrate (PC) 
and keratinocytes suspended in autologous platelet concentrate (PC+ K). Split thickness skin graft donor sites were 
chosen on the anterolateral thighs of patients undergoing plastic surgery for a variety of defects. Wound healing 
was assessed by the duration and quality of the healing process. Pain intensity was evaluated at day five. 
Results: Healing time was reduced from 13.9 ± 0.5 days (mean ±SEM) in the control group to 7.2 ± 0.2 days in the 
PC group (P < 0.01). An addition of keratinocytes in suspension further reduced the healing time to 5.7 ± 0.2 days. 
Pain was reduced in both the PC and PC+ K groups. Data showed a statistically detectable advantage of using PC+ K 
over PC alone (P < 0.01). 
Conclusion: The results demonstrate the positive contribution of autologous platelets combined with keratinocytes in 
stimulating wound healing and reducing pain. This strikingly simple approach could have a significant impact on 
patient care, especially critically burned victims for whom time is of the essence. 
Clinical trial registry information: Protocol Record Identification Number: 132/03 
Registry URL: http://www.clinicaltrials.gov 
Background 
Despite the progress achieved in the past few decades, 
wound healing remains a difficult issue to which modern 
medicine does not always have an efficient response. 
The surgical treatment of wounds focuses primarily on 
accelerating the healing process and overcoming the ini-
tial danger and deleterious consequences associated with 
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bleeding and infection. However, under certain circum-
stances, surgery is not an option. As such, methods like 
hemotherapy, which consists of applying dressings 
soaked in blood to the wound itself, have been applied 
in order to accelerate the healing of certain difficult 
wounds. Physicians who used this treatment were un-
aware that they were in fact treating wounds with 
growth factors [1,2]. 
In recent years, new treatments focusing on dressing 
design and composition have been suggested to acceler-
ate wound healing. The ideal dressing should be easy to 
© 2013 Guerid et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (httpJ/creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
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use, allow the absorption of blood and secretions, reduce 
local pain and permit a pain-free dressing replacement 
[3,4]. Affordability is also an important factor. Novel 
'smart' dressings have indeed been designed to cover 
graft donor sites and stimulate their healing time. How-
ever, none satisfies ail the criteria mentioned above, 
hence the importance of researching other tools. Specific 
growth factors such as platelet-derived growth factor 
(PDGF), epidermal growth factor (EGF) and fibroblast 
growth factor (FGF) have been used in topical treat-
ments [5] but results published thus far are inconclusive, 
probably because of the complexity of the healing 
phenomenon which cannot be stimulated by the local 
application of one factor at any given time, especially 
since the dosages are often well above physiological 
levels. Indeed, the orchestrated release of growth factors 
must be respected in order to best emulate the physio-
logical process [6-8]. Therefore, even with increased pre-
cision in surgical technique, post-operative smart 
dressings, administration of growth factors and regular 
use of nutritional supplements, reported healing time 
and risk of complications remained unchanged [9,10], 
resulting in inconsistent ' and disappointing outcomes 
with dissuasive treatment costs. 
Platelets play a fundamental role in wound healing, 
primarily through the formation of platelet dots and the 
release of many growth factors and cytokines [5]. It has 
also been shown that epidermal keratinocytes play an 
essential role in wound healing [11-17]. Keratinocytes, 
when applied to a wound, should theoretically induce 
and stimulate healing by releasing growth factors or 
multiplying in situ [18], thereby enhancing the healing 
effect of blood platelets. Theoretically, it is possible to 
amplify the effects of the first steps of the wound healing 
cascade by increasing the local concentration of platelets 
and keratinocytes which would then induce an increased 
production of trophic and growth factors [19-23]. 
A prospective randomized study with three groups of 
patients was performed in order to test whether a plate-
let concentrate or keratinocytes suspended in a platelet 
concentrate could enhance wound healing. One experi-
mental group was treated with an autologous platelet 
concentrate, another experimental group received a sus-
pension of autologous keratinocytes combined with a 
platelet concentrate while a standard treatment was ad-
ministered to patients in the control group. 
Methods 
Study design 
The clinical study was conducted as a prospective, ran-
domized controlled, blinded phase I trial (Protocol Rec-
ord 132/03; http://www.clinicaltrials.gov). After approval 
by the institutional ethics committee and the Swiss 
agency for therapeutic products (Swissmedic), 45 pa-
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tients aged between 18 and 80 years and presenting graft 
donor sites not exceeding 15% of their total body surface 
were enrolled in the study between June 2005 and 
March 2006 at the Lausanne University Hospital in 
Switzerland. Each collected skin graft was 0.2 mm in 
thickness, located on the anterolateral region of the 
thigh and corresponding to a mean area of 180cm2 
(range 25 to 200 cm2). Skin grafts were collected by 
means of a dermatome (Aesculap AG, Tuttlingen, 
Germany) with a thickness of 0.2 mm, which is the 
standard in our department in burn patients in order to 
achieve healing. In order to create comparable wounds, 
we used the same protocol in all patients. Exclusion cri-
teria were: treatment with immunosuppressors or corti-
coids, terminal renal insufficiency and severe peripheral 
arteriopathy. Patients were randomized to one of three 
groups of 15 patients: control, platelet concentrate (PC) 
and platelet concentrate with keratinocytes (PC + K) 
(Table 1). Block randomization was generated using a 
computer program (S-Plus 4.0 for Windows, Microsoft 
Schweiz, Richtistrasse 3, 8304 Wallisellen (Zurich), 
Switzerland) by an investigator with no clinical involve-
ment in the trial. Allocation was concealed from patients 
and observers. 
Platelet isolation 
At the initiation of surgery, an 8.5 cc blood sample was 
collected from a vein in the upper arm without IV perfu-
sion by means of a RegenKit" (RegenLab, En Budron B2, 
1052 Le Mont-sur-Lausanne, Switzerland). The blood 
sample tube was immediately centrifuged for eight mi-
nutes at 2,800 rpm leading to a separation of the red 
cells from the plasma. Under these conditions, the plate-
lets formed a narrow white band at the interface be-
tween the red cells and the plasma. After resuspending 
the platelets in the plasma by gentle agitation, the 
resulting platelet concentrate was transferred to another 
sterile tube and placed at 37°C. The final volume of 
platelet concentrate ranged between 3.5 and 4.5 ml. PC 
Table 1 Patient population characteristics 
Group Contrai PC PC+ K 
(n= 15) (n= 15) (n = 15) 
Age in years, 42.5±3.1 (39) 45.5 ± 3.9 (48) 46.9 ± 5.3 (54) 
rnean±SEM 
(rnedian) 
Gender, M: F 11: 4 9:6 5: 10 
Diagnosis, nurnber (%) 
Trauma 7 (47) 3 (20) 3 (20) 
Burn 2 (13) 6 (40) 4 (27) 
Ulcer 2 (13) 1 (7) 3 (20) 
Cutaneous tumors 0 (0) 4 (27) 0 (0) 
Others 4 (27) 1 (7) 5 (33) 
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were controlled for cell type and concentration: some 
isolated mononuclear cells were observed 
Autologous keratinocyte isolation 
A sample of 0.2 mm thick skin collected by means· of a 
dermatome was placed in a transport tube containing 
20 ml of DMEM, 102 U/ml of penicillin and 0.1 mg/ml 
of streptomycin sulfate. The skin sample was sent along 
with the platelet concentrate to our cell culture labora-
tory. After being rinsed three times with an isotonie PBS 
solution, the skin sample was eut into small fragments 
(approximately 1 mm2) with a scalpel and digested in a 
0.05% trypsin - 0.01 % EDTA mixture for 45 minutes at 
37'C. The supernatant containing the keratinocytes was 
centrifuged for three min at 200 g and the resulting cell 
pellet was washed twice in DMEM solution. The cells 
were then counted under the microscope. Finally, the 
cell pellet was suspended in 3.5 to 4.5 ml of autologous 
platelet concentrate. All procedures were conducted 
under a laminar flow, following strict rules of asepsis 
and sterility in a cell processing center, according to the 
GMP procedures. 
Surgical treatment 
After collecting skin grafts, all donor sites were tempor-
arily covered with gauze impregnated with an adrenaline 
solution (2 mg/L in saline). At the end of the surgical 
intervention, the PC group received a platelet concen-
trate obtained using the procedure described above. A 
spray applicator consisting of two syringes maintained at 
37'C, one containing PC (10 volume) and the other a 
10% calcium chloride solution (1 volume), was used to 
dispense the mixture on to the wound bed. The mix-
tures were left to coagulate in situ before applying any 
dressings. Mean cell counts in suspension for 4 ml were 
2,300 x 106 platelets and 22.6 x 106 keratinocytes. Aver-
age counts on wounds were 13.5 x 106/cm2 platelets and 
80,000 keratinocytes/cm2 respectively. The PC+ K group 
received a suspension of keratinocytes in PC following a 
similar procedure. Wounds from all groups were then 
covered with three layers of paraffin gauze (Jelonet•, 
Smith & Nephew, 15 Adam Street, London WC2N 6LA, 
UK), wrapped with standard bandages (Kerlix0 , Covidien, 
15 Hampshire Street, Mansfield, Ma) and contained in 
an elastic bandage. Control wounds were covered by 
three layers of paraffin gauze and bandages (the standard 
treatment for skin graft take in our department). All pa-
tients and observers were blinded to the treatment. 
Wound healing 
Treatment efficiency was evaluated with respect to the 
duration (in days) until complete healing occurred along 
with assessments of the degree of epithelialization. The 
first evaluation was done on post-operative day five by 
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an observer blinded to the type of treatment. The dress-
ing and bandages were replaced with sheets of paraffin 
gauze and covered with standard dry dressings. Subse-
quent evaluations were done at two-day intervals until 
complete healing. Time until complete wound healing 
was recorded. Local pain, in general and specifically 
while replacing dressings, was evaluated by the patients 
on post-operative day five using a visual analogical scale 
with 0 representing no pain and 10 representing extreme 
pain. Both pre-operative and post-operative pictures 
documenting wound healing progression were also 
taken. Eventual adverse effects were to be recorded 
throughout the follow-up. 
Statistical analysis 
Results are expressed as mean ±SEM. One-way ANOVA 
and post hoc Tukey's tests were used to confirm sta-
tistically detectable differences between groups with 
P-values below 0.05. The statistical package was JMP 0 
(Version 5.5, SAS Institute Inc., Cary, NC, USA). 
Results 
Altogether, 45 patients were included (Table 1). There 
were no statistically significant differences between the 
groups with respect to gender and age despite the PC+ K 
group having a ratio of female to male patients which was 
almost the inverse of that in other groups. The four most 
frequent pathologies in our groups were traumatic defects, 
burns, ulcer of venous etiology and cutaneous tumors. In 
the control group, the other categories consisted of one 
lumbar hemolymphangioma, one equinous deformity with 
neurinoma, one excision of a thigh sarcoma and one de-
fect after total knee arthroplasty. In the PC group, there 
was only one patient outside the aforementioned categor-
ies. This case was a carcinoma of the rectum needing skin 
graft after perineal reconstruction. In the PC + K group, 
there were five patients not belonging to the main categor-
ies. These consisted of one hidradenitis suppurativa, one 
thigh sarcoma, one necrotizing pancreatitis, one ankle os-
teitis with secondary flap reconstruction and one keloid 
excision. 
W ound healing was significantly shortened in PC and 
PC+ K groups compared to control (P < 0.01), reflecting 
the stimulation of wound healing by the platelet concen-
trate (Figure lA). In the PC group, wound healing time 
was reduced to 7.2 ± 0.2 days compared with 13.9 ± 0.5 
days in the control. A further significant reduction of 
the healing time was observed in the PC + K group com-
pared to the PC group (P < 0.01). Indeed, the PC+ K 
group showed the fastest wound healing, averaging 5.7 ± 
0.2 days (Figure 2). 
Patients from the PC group also experienced a signifi-
cant reduction of the pain resulting from the skin graft 
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Figure 1 Results show a significant reduction in time to wound 
healing associated with less pain. (A) Duration in days until 
complete wound healing. (B) Pain intensity reported on post-
operative day five using a visual analogical scale. Data as box plots 
(sample minimum, lower quartile, median and upper quartile as well 
as sample maximum). 
donor sites compared to the contrai group, an effect fur-
ther enhanced in the PC+ K group (Figure lB). 
No infection was noted. The tolerance and acceptance 
of the treatments were excellent and no undesirable ef-
fects were noted. 
Discussion 
Studying clinical wound healing is challenging because 
of an inherently high variability, which may alter the 
evaluation of results. The principal differences lie within 
the wound itself, specifically its depth, localization, eti-
ology and other associated pathologies [24]. This moti-
vated our aim to evaluate skin graft donor sites rather 
than the grafted areas in an attempt to minimize inher-
ent differences between wounds. Indeed, a skin graft re-
mains the most used technique for wound closure 
[25,26] and the surgical technique has been refined over 
the years due to improvement of the apparatus used to 
take skin grafts. This now allows for an increased preci-
sion and reproducibility. For this reason and due to the 
relative ease of monitoring donor sites, this type of 
wound has become the ideal model to study wound 
healing in vivo [26]. Healing of the donor site, however, 
may vary and depends on bath the depth of the wound 
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and its surface area which may range from a few square 
centimeters to several hundred. The energy cost of 
healing is elevated and aggravated by lasses of minerais, 
trace elements, proteins and fluids [25,26]. This becomes 
particularly important when extensive surfaces are in-
volved, as in the case of major burns, major trauma, and 
in children and elderly patients. In those cases, new 
large wounds appear at skin graft donor sites, with an el-
evated risk of complication such as infections and de-
layed healing which further increases the toll on the 
body. It is therefore, extremely important to attempt to 
stimulate and accelerate donor site wound healing [27]. 
Under normal circumstances, and according to the in-
clusion criteria we defined, the graft donor sites investi-
gated in this study should heal spontaneously within 12 
to 14 days. Encouraging results were obtained while 
assessing the healing effect of the application of an au-
tologous platelet concentrate alone and the application 
of a keratinocyte suspension combined with an autolo-
gous platelet concentrate to the donor site compared to 
a standard treatment. Indeed, clinical efficacy was not-
ably enhanced as experimental groups showed an 
important reduction of healing time, particularly in the 
PC + K group which only required an average of five 
days, less than half the time required by conventional 
methods (Figure lA). These results show the ability of 
concentrated platelets and keratinocytes to amplify and 
enhance the first phases of the healing cascade. In our 
trial, we didn't include a group of patients receiving 
keratinocytes only, because previous work has already 
demonstrated its benefit on wound healing [28-31] and 
because our purpose was to verify the use of PC as a 
transport medium for keratinocytes. 
Our study also confirms that platelet concentrates may 
be successfully obtained through a one-step isolation 
procedure. The protocols used in this study however, 
may of course be further optimized. For instance, al-
though the platelet concentrates were prepared during 
the surgical intervention, it may be possible to do so on 
the eve of the operation, thereby effectively reducing the 
workload in the operating room. Similarly, we are cur-
rently investigating ways to further simplify methods of 
obtaining cutaneous cell suspensions and to better 
understand their contribution to enhancing the healing 
cascade and their interaction with the delivered platelets. 
Different types of dressings such as hydrocellular, 
hydrocolloid, alginates and paraffin gauze have been 
tested in our department during the past few years in an 
attempt to reduce pain. Although subsiding with the use 
of some hydrocellular dressings, pain and discomfort 
almost always remained a problem during dressing re-
placement which is clone imperatively in the first 48 
hours and a week following the procedure [3,9,32]. The 
elevated cost per unit of the above mentioned dressing 
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Figure 2 Pictures demonstrate greater amount of epithelialization when treated with platelet concentrate or keratinocytes suspended 
in a platelet concentrate. (A) and (B) show treatment with PC at operation t ime (left panel) and seven days later (ri ght panel). (C) and (D) show 
treatment with PC+ K at operation time (left panel) and five days later (right panel). 
however becomes consequential relative to the wound 
surface to be covered (9,33,34] . 
The study shows significant pain reduction when using 
PC alone, and an even more pronounced reduction using 
the combination of PC with keratinocytes (Figure lB). The 
effect was virtually immediate and long lasting and 
without the need for repeated application. Sorne patients 
who had previously healed skin graft donor site wounds 
noted the difference in treatment and found the recovery 
relatively pain free. This admittedly unforeseen observa-
tion could be partially explained by the ability of the plate-
let gel to maintain a humid environment around the 
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wound. Different kinds of new dressings (for example, 
hydrofibers and hydrocolloids), however, attempt to gene-
rate that same effect although the pain does not disappear 
completely and is usually only attenuated, hinting that 
there may be more to the story. Indeed, platelets may be 
releasing or stimulating the release of substances with an 
analgesic effect. As shown previously [35], platelets are 
known to release endorphins, which may explain why the 
analgesic effect observed was rapid and long lasting. W e 
have noted the same observation in patients presenting 
chronic wounds and treated with platelet gels (data not 
shown). Specific studies must be conducted to explain pre-
cisely how the platelet concentrates act directly or indir-
ectly on pain in acute wounds and how keratinocytes may 
further enhance that effect, as we have seen in this study. 
The risk of wound infection is directly related to the 
healing time, while delayed wound healing may in cer-
tain cases be the only sign of infection [9,10,36-38]. This 
can be explained by the bacterial release of endotoxins 
that increase pro-inflammatory cytokines such as 11-1 
and TNF-a, thereby causing increased levels of 
metalloproteinases (MMPs) and a decrease in the pro-
duction of growth factors [36]. Additionally, wound in-
fections increase exudates and pain and are associated 
with increased patient discomfort, an unesthetic scar 
and an important increase in the cost of care. As such, 
infection of the donor site may sometimes expand, espe-
cially in debilitated, malnourished, polytraumatized pa-
tients, major burn victims or patients treated with drugs 
that render the skin fragile, such as corticoids. Ranging 
from cellulitis to septicemia, complications may very 
well threaten the patient's survival. 
No infectious complication was observed in this study. 
This can be explained by the acceleration of healing and 
the potential antibacterial role of platelets and white 
blood cells trapped in the platelet concentrate [39,40]. 
Additional studies may shed some light onto the mecha-
nisms underlying this effect and whether platelets act 
directly to prevent infections or through the stimulation 
or other cells. Whether cutaneous cell suspensions help 
enhance this effect would also be of interest, especially 
in the case of chronic wounds. 
The methods presented here benefit from an import-
ant advantage in that no heterologous product was used. 
PC can be obtained by simple centrifugation with a 
Conformité Européenne (CE) approved device. This 
study also demonstrates that platelet concentrate may be 
an excellent vehicle for transporting a suspension of au-
tologous keratinocytes onto a wound. Keratinocytes, 
which play an essential role in wound healing thanks to 
their multiplicative capacity and their metabolic role 
[11-17], effectively enhance the effect of PC, an observa-
tion which opens the door to a much larger range of ap-
plications involving the addition of other cell types such 
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as fibroblasts, which also play an important role in 
wound healing [7]. In the case of major burns, every day 
gained in terms of healing translates into increased 
chances of survival, reduced suffering, reduced scar ran-
som and an important decrease in what is usually a 
major cost to health institutions. The preparation of a 
PC requires a cell processing unit and qualified 
personnel for cell isolation. The laboratory procedure 
takes approximately 90 minutes. Taking into account the 
personnel salary and the kit for platelet isolation, the 
cost of a PC + keratinocyte preparation may be estimated 
between 300 to 500 Swiss Francs. There is no major ma-
nipulation of the tissue, including cell culture and ex-
pansion. As only enzymatic treatment and centrifugation 
steps are needed, tissue can be rapidly processed in a 
Class A laminar flow system dedicated for this activity. 
Conclusion 
The data show that platelet concentrates have a bene-
ficial effect on wound healing and can be used to de-
liver keratinocytes to the wounds. The association of 
platelet concentrates and keratinocytes appears to be 
the most efficient way to enhance wound healing. We 
believe that this method could be the first line treat-
ment for patients with impaired healing. However, the 
complexity and cost of the method have to be re-
duced in order for this technique to be used as a 
standard protocol. 
This study showed beneficial effects regarding pain 
and time to complete wound healing. This procedure 
opens the path towards a more efficient treatment of 
chronic wounds such as ulcers, including decubitus 
ulcers and those related to diabetic neuropathies or 
necrotic angiodermatitis. It also provides undeniable 
advantages in treating major burn victims. Future tri-
als are required to address the question of the spe-
cific impact of keratinocytes on wound healing. 
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